GLP-1 Less Frequent Dosing May Maintain Weight Loss
A study of real-world and virtual patients suggests that a less frequent dosing of glucagon-like peptide 1 receptor agonists is an effective and cost-saving strategy for long-term weight maintenance. Medscape Medical News
US administration will set targets to slash drug prices
What’s happened? On May 12th US president Donald Trump issued an executive order (EO) announcing plans to drastically lower prescription drug prices in the country. The order kickstarts negotiations that aim to force pharmaceutical companies to cut their US prices to match those charged in other developed countries, on a “most-favoured nation” basis. While the […]
Biocon gets CDSCO nod for generic diabetes medication
Biocon has secured Indian regulatory approval for its generic Liraglutide drug substance and product, a version of Victoza, for treating Type 2 Diabetes in adults and children over 10. CEO Siddharth Mittal highlighted the importance of this vertically integrated GLP-1 drug in expanding access for diabetes patients in India, where cases are rapidly increasing.
Forget needles, fat-jab PILLS are here: Why they’re cheaper, how much weight you could lose & the side effects revealed
EVERYONE’S talking about fat jabs – the ‘miracle’ injections trimming inches off waistlines, and helping turn the tide on the obesity epidemic. But what if there was an even easier – and cheaper – way than Ozempic-like injections, Wegovy and Mounjaro? GettySlimming tablets have been around for decades – but now scientists want to harness […]
8 Ways to Boost the Effects of Ozempic and Other GLP-1 Drug Treatments
According to leaders in obesity and nutrition research, following these key nutrition guidelines will make the most of GLP-1 drug treatment.
MAHA Agenda Excludes GLP-1 Coverage Expansion
PharmaVoice article discusses the Trump administration’s decision not to expand Medicare and Medicaid coverage for GLP-1 obesity drugs, despite their increasing use and the potential for significant market growth for companies like Eli Lilly and Novo Nordisk. Although a Biden-era proposal to expand coverage was rejected due to concerns about the high cost to the federal government, […]
Regeneron pens $2B pact for Hansoh’s potential obesity rival to Lilly’s Zepbound
Regeneron is paying Hansoh Pharma $80 million upfront for a phase 3-stage GLP-1/GIP receptor agonist the companies believe can hold its own against Eli Lilly’s Zepbound.
Could Viking Therapeutics Become the Next Eli Lilly?
The obesity treatment market is booming, with groundbreaking drugs like Eli Lilly‘s (NYSE: LLY) Zepbound delivering transformative patient results and powering its stock to a spectacular 400% return in the past five years. Amid this estimated $100 billion opportunity, much smaller upstart Viking Therapeutics (NASDAQ: VKTX) has emerged with a promising clinical pipeline, aiming to […]
Mainland Chinese market for weight loss and diabetes drugs to soon be more crowded: report
2025.06.02 10:36 Novo Nordisk’s semaglutide product. Photo: Handout Competition in the mainland Chinese market for diabetes and weight loss drugs is set to intensify as more than 60 late-stage drug candidates are undergoing clinical trials, according to a recent report. Up to 20 biosimilar or generic copies will vie for market share and add pricing […]
“I’m Thin, And I’m Yellow”: Doctors Sound Alarm On Concerning New Ozempic Side Effect
The “miracle weight-loss drug” Ozempic, once hailed as a shortcut to shedding pounds without the hard work, is now at the center of an alarming health scare. Dozens of Australians taking semaglutide-based medications—Ozempic, Wegovy, and Mounjaro—have come forward with reports of dr*g-induced hepatitis, a form of liver inflammation caused by medications or toxins. Some patients […]